IPH 2101 / Novo Nordisk, Innate - LARVOL DELTA

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial (ASH 2017) - P2; "...Lirilumab is a 2nd generation anti-KIR mAb currently evaluated in multiple indications and combinations with encouraging preliminary results in combination with nivolumab in pts with squamous cell carcinoma of the head and neck (Leidner, SITC 2016)...Consolidation chemotherapy consisted of intermediate-dose single agent cytarabine (IDAC) in 53%, and 5+1 in 47% of the pts, according to the recommendations of the ALFA and FILO cooperative groups, respectively...Single agent lirilumab administered for up to 24 cycles was well tolerated. Lirilumab did not result in a statistically significant improvement of LFS in the challenging setting of maintenance in AML in elderly pts. Immune-pharmacological studies will be presented."

Clinical • P2 data • Acute Myelogenous Leukemia • Biosimilar • Dermatology • Head and Neck Cancer

Innate: Company Presentation (Innate Pharma) - "Phase I dose-escalation of IPH201 in combination with lenalidomide (LEN) in 15 patients with relapsed/refractory MM"; "Prior therapies: one prior line: 10 pts; 2 prior lines: 5 pts; prior LEN: 10 pts"; "Treatment: 4 cycles of IPH2101 and LEN; 5 pts received 4 additional cycles; No use of corticosteroids"; "Results: Combination generally well tolerated; IPH2101 PK and PD not affected by co-administration of LEN; Objective responses observed in 33.3% of patients with and without prior LEN exposure, Median PFS of 24 months"

P1 data • Multiple Myeloma • Oncology

Innate: Corporate Presentation (Innate Pharma) - “Elderly AML patients in complete remission after induction and consolidation treatment – maintenance setting”; “Phase I dose-escalation including 23 patients in first CR, and extension including 12 patients”; “Doses ranged from 0.0003 to 3 mg/kg – Full KIR saturation at doses ≥1mg/kg”; “Good tolerance with mild and transient adverse events. MTD not reached. Clear PK/PD relationship”; “Clinical outcome (2 patients from extension excluded, one in CR2 and one for early relapse within 5-days”

P1 data • Acute Myelogenous Leukemia • Oncology

Emerging immune targets for the treatment of multiple myeloma. (PubMed, Immunotherapy) - "...Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab...A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising."

Journal

Evaluation of Air Polishing With Ultrasonic Debridement in the Treatment of Initial Periodontal Pockets (clinicaltrials.gov) - P=N/A; N=15; Recruiting; Sponsor: Syrian Private University

Clinical • Clinical data • New trial